Advertisement

Clinical Pharmacokinetics

, Volume 8, Issue 4, pp 332–343 | Cite as

Clinical Pharmacokinetics of Narcotic Agonist-Antagonist Drugs

  • R. E. S. Bullingham
  • H. J. McQuay
  • R. A. Moore
Review Article

Summary

Narcotic agonist-antagonist drugs are able specifically to reverse the effects of morphine and other opiate agonists in some pharmacological preparations. They also have some agonist properties which in some cases may be extensive and provide useful clinical properties such as analgesia, or may be minimal. Thus pentazocine, buprenorphine, nalbuphine and butorphanol all demonstrate definite analgesic properties. Naltrexone, in contrast, has only limited agonist action, as shown for example in pupil constriction, and is perhaps better regarded as an antagonist.

After intravenous administration of buprenorphine there is an initially rapid early distribution phase with a half-life of about 2 minutes. Studies on butorphanol and pentazocine had insufficient early samples to allow accurate analysis of this phase. Otherwise, the intravenous pharmacokinetics for all these drugs show bi- or tri-exponential decay with terminal half-lives of between 3 and 5 hours, plasma clearances of between 1200 and 2800 ml/min, and apparent volumes of distribution of 200 to 400L. These values for plasma clearance and terminal half-life have been confirmed in oral and intramuscular studies.

There is only limited information about the rate or extent of absorption after intramuscular administration. For buprenorphine peak plasma concentrations are reached between 2 and 5 minutes; for pentazocine and butorphanol the peak is later, at between 15 and 60 minutes for pentazocine and 45 minutes for butorphanol. Systemic availability of intramuscular buprenorphine is in the range of 40 to 100%, but is generally greater than 90%. Availability of intramuscular butorphanol has been reported to be complete.

Oral systemic availability for drugs with a high plasma clearance is predictably low because of a significant first-pass effect through the liver. The oral availabilities of pentazocine and nalbuphine have been calculated to be about 20%, and although there are no pharmacokinetic data, some evidence of clinical efficacy suggests a similar figure for butorphanol and buprenorphine. For naltrexone however, the available data suggest that this drug is completely absorbed after oral administration.

Only buprenorphine has been studied by the sublingual route. The systemic availability was variable (16 to 94%), but on average it was 55% in a study of long duration; the absorption half-life from the buccal cavity was estimated to be 76 minutes. Over a limited dose range there appeared to be linear increases in the maximum rise in plasma concentration and AUC with buprenorphine administered by this route. There have been no pharmacokinetic studies of the narcotic agonist-antagonist drugs by other routes of administration, such as after intrathecal or extradural administration, or rectally or transcutaneously.

Pharmacodynamic data for these drugs are incomplete. Analgesia in man appears to be dose-related for pentazocine, butorphanol, buprenorphine and nalbuphine; morphine antagonism is dose-related for naltrexone. The appearance of opiate side effects (nausea and drowsiness) is reported to be dose-related for pentazocine, butorphanol and buprenorphine.

‘Ceiling’ effects on respiratory depression in man are found for pentazocine, butorphanol, buprenorphine and nalbuphine. For pupillary effects, there is evidence for a ceiling effect for nalbuphine and naltrexone, but dose-related effects for buprenorphine. Some of the neuroendocrine effects of buprenorphine and butorphanol appear to be dose-related, but there has been little work done in this area.

Keywords

Morphine Buprenorphine Naltrexone Hepatic Blood Flow Pentazocine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adriansen, H.; Mattelaere, B. and Vanmeenen, H.: A long-term open assessment of sublingual buprenorphine in patients suffering from chronic pain (abstract). Pain Suppl. 1: S38 (1981).CrossRefGoogle Scholar
  2. Agurell, S.; Boreus, L.G.; Gordon, E.; Lindgren, J.E.; Ehrnebro, M. and Lonroth, U.: Plasma and cerebrospinal fluid concentrations of pentazocine in patients: Assay by mass fragmentography. Journal of Pharmacy and Pharmacology 26: 1–8 (1974).PubMedCrossRefGoogle Scholar
  3. Bartlett, A.J.; Lloyd-Jones, J.G.; Rance, M.J.; Flockhart, I.R.; Dockray, G.; Bennett, M.R.D. and Moore, RA.: The radioimmunoassay of buprenorphine. European Journal of Clinical Pharmacology 18: 339–345 (1980).PubMedCrossRefGoogle Scholar
  4. Beaver, W.T. and Feise, G.A.: A comparison of the analgesic effect of intramuscular nalbuphine and morphine in patients with postoperative pain. Journal of Pharmacology and Experimental Therapeutics 204: 487–496 (1978).PubMedGoogle Scholar
  5. Beckett, A.H. and Taylor, J.F.: Blood concentrations of pethidine and pentazocine in mother and infant at time of birth. Journal of Pharmacy and Pharmacology 19 (Suppl.): 50 (1967).Google Scholar
  6. Berkowitz, B.: Pharmacokinetics and neurochemical effects of pentazocine and its optical isomers. Advances in Biochemical Psychopharmacology 8: 495–501 (1974).Google Scholar
  7. Berkowitz, B.; Asling, J.H.; Schnider, S.M. and Leong-Way, E.: Relationship of pentazocine plasma levels to pharmacological activity in man. Clinical Pharmacology and Therapeutics 10: 320–328 (1969).PubMedGoogle Scholar
  8. Blumberg, H. and Ikeda, C.: Comparison of naltrexone and β-naltrexol for narcotic antagonist action in rats and mice (abstract). Federation Proceedings 35: 469 (1976).Google Scholar
  9. Branch, R.A.; Shand, D.G.; Wilkinson, G.R. and Nies, A.S.: The reduction in lidocaine clearance by DL-propranolol: An example of hemodynamic drug interaction. Journal of Pharmacology and Experimental Therapeutics 104: 515–519 (1973).Google Scholar
  10. Brewster, D.; Humphrey, M.J. and McLeavy, M.A.: Biliary excretion, metabolism and enterohepatic circulation of buprenorphine. Xenobiotica 11: 189–196 (1981).PubMedCrossRefGoogle Scholar
  11. Brogden. R.N.; Speight, T.M. and Avery, G.S.: Pentazocine: A review of its pharmacological properties, therapeutic efficacy and dependence liability. Drugs 5: 6–91 (1973).PubMedCrossRefGoogle Scholar
  12. Budd. K.: High dose buprenorphine for postoperative analgesia. Anesthesia 36: 900–903 (1981).CrossRefGoogle Scholar
  13. Bullingham, R.E.S.; McQuay, H.J.; Dwyer, D.; Allen, M.C. and Moore, R.A.: Sublingual buprenorphine used postoperatively: Clinical observations and preliminary pharmacokinetic analysis. British Journal of Clinical Pharmacology 12: 117–122 (1981a).PubMedCrossRefGoogle Scholar
  14. Bullingham, R.E.S.; McQuay, H.J. and Moore, R.A.: Intrathecal and extradural narcotics. Recent Advances in Anaesthesia and Analgesia 14: 141–156 (1982a).Google Scholar
  15. Bullingham, R.E.S.; McQuay, H.J.; Moore, R.A. and Bennett, M.R.D.: Buprenorphine kinetics. Clinical Pharmacology and Therapeutics 28: 667–672 (1980).PubMedCrossRefGoogle Scholar
  16. Bullingham, R.E.S.; McQuay, H.J.; Moore, R.A. and Weir, L.: An oral buprenorphine and paracetamol combination compared with paracetamol alone: A single dose double-blind postoperative study. British Journal of Clinical Pharmacology 12: 863–867 (1981b).PubMedCrossRefGoogle Scholar
  17. Bullingham, R.E.S.; McQuay, H.J.; Porter, E.J.B.; Allen, M.C. and Moore, R.A.: Sublingual buprenorphine used postoperatively: Ten hour plasma drug concentration analysis. British Journal of Clinical Pharmacology 13: 665–673 (1982b).PubMedCrossRefGoogle Scholar
  18. Cone, E.J. and Gorodetsky, C.W.: New metabolites of naltrexone and naloxone in man and several laboratory species (abstract). Federation Proceedings 35: 469 (1976).Google Scholar
  19. Cone, E.J.; Gorodetsky, C.W. and Yeh, S.Y.: The urinary excretion profile of naltrexone and metabolites in man. Drug Metabolism and Disposition 2: 506–512 (1974).PubMedGoogle Scholar
  20. de Klerk, G.; Mattie, H. and Spierdijk, J.: Comparative study on the circulatory and respiratory effects of buprenorphine and methadone. Acta Anaesthesiologica Belgica 32: 131–139 (1981).PubMedGoogle Scholar
  21. Difazio, C.A.; Moscicki, J.C. and Magruder, M.R.: Anesthetic potency of nalbuphine and interaction with morphine in rats. Anesthesia and Analgesia 60: 629–633 (1981).PubMedCrossRefGoogle Scholar
  22. Dobkin, A.B.; Eamkaow, S. and Caruso, F.S.: Butorphanol and pentazocine in patients with severe postoperative pain. Clinical Pharmacology and Therapeutics 18: 547–533 (1975).PubMedGoogle Scholar
  23. Ehrnebro, M.; Agurell, S.; Boreus, L.O.; Gordon, E. and Lonroth, U.: Pentazocine binding to blood cells and plasma proteins. Clinical Pharmacology and Therapeutics 16: 424–428 (1974).Google Scholar
  24. Ehrnebro, M.; Boreus, L.O. and Lonroth, U.: Bioavailability and first-pass metabolism of oral pentazocine in man. Clinical Pharmacology and Therapeutics 22: 888–892 (1977).Google Scholar
  25. Engineer, S. and Jennett, S.: Respiratory depression following single and repeated doses of pethidine and pentazocine. British Journal of Anaesthesia 44: 795–801 (1972).PubMedCrossRefGoogle Scholar
  26. Gaver, R.C.; Vasiljev, M.; Wong, H.; Monkovic, I.; Swigor, J.E.; van Harken, D.R. and Smyth, R.D.: Disposition of parenteral butorphanol in man. Drug Metabolism and Disposition 8: 230–235 (1980).PubMedGoogle Scholar
  27. Gilben, M.S.; Forman, R.S.; Moylan, D.S. and Caruso, F.S.: Butorphanol: A double-blind comparison with pentazocine in postoperative patients with moderate to severe pain. Journal of International Medical Research 4: 255–264 (1976).Google Scholar
  28. Hambrook, J.M. and Rance, M.J.: The interaction of buprenorphine with the opiate receptor; in Kosterlitz (Ed.) Opiates and Endogenous Opioid Peptides, pp.295–301 (Elsevier/North Holland Biomedical Press, Amsterdam 1976).Google Scholar
  29. Heel, R.C.; Brogden, R.N.; Speight, T.M. and Avery, G.S.: Buprenorphine: A review of its pharmacological properties and therapeutic efficacy. Drugs 17: 81–110 (1979).PubMedCrossRefGoogle Scholar
  30. Hoffman, J.C. and DiFazio, C.A.: The anesthesia-sparing effect of pentazocine, meperidine and morphine. Archives Internationales de Pharmacodynamic et de Therapie 186: 261–268 (1970).Google Scholar
  31. Jasinski, D.R. and Mansky, P.A.: Evaluation of nalbuphine for abuse potential. Clinical Pharmacology and Therapeutics 13: 78–90 (1972).PubMedGoogle Scholar
  32. Jasinski, D.R.; Pevnick, J.S. and Griffith, J.D.: Human pharmacology and abuse potential of the analgesic buprenorphine. Archives of General Psychiatry 35: 501–516 (1978).PubMedCrossRefGoogle Scholar
  33. Juhl, B. and Einer-Jensen, N.: Hepatic blood flow and cardiac output during halothane anaesthesia: An animal study. Acta Anaesthesiologica Scandinavica 18: 114–122 (1974).PubMedCrossRefGoogle Scholar
  34. Kallos, T. and Caruso, F.S.: Respiratory effects of butorphanol and pethidine. Anaesthesia 34: 633–637 (1979).PubMedCrossRefGoogle Scholar
  35. Kogan, M.J.; Verebey, K. and Mulé, S.J.: Estimation of the systemic availability and other pharmacokinetic parameters of naltrexone in man after acute and chronic oral administration. Research Communications in Chemical Pathology and Pharmacology 18: 29–34 (1977).PubMedGoogle Scholar
  36. Ludden, T.M.; Malspeis, L.; Baggot, J.D.; Sokolaski, T.D.; Frank, S.G. and Reuning, R.H.: Tritiated naltrexone binding in plasma for several species and tissue distribution in mice. Journal of Pharmaceutical Sciences 65: 712–716 (1976).PubMedCrossRefGoogle Scholar
  37. McQuay, H.J.; Bullingham, R.E.S.; Paterson, G.M.C. and Moore, R.A.: Clinical effects of buprenorphine during and after operation. British Journal of Anaesthesia 52: 1013–1019 (1980).PubMedCrossRefGoogle Scholar
  38. Maduska, A.L. and Hajghassemali, M.: A double-blind comparison of butorphanol and meperidine in labour: Maternal pain relief and effect on the newborn. Canadian Anaesthetists Society Journal 25: 398–404 (1978).PubMedCrossRefGoogle Scholar
  39. Martin, W.R.: History and development of mixed opioid agonists, panial agonists and antagonists. British Journal of Clinical Pharmacology 7: 273S–277S (1979).PubMedCrossRefGoogle Scholar
  40. Mello, N.K. and Mendelson, J.H.: Buprenorphine suppresses heroin use by heroin addicts. Science 207: 657–659 (1980).PubMedCrossRefGoogle Scholar
  41. Mendelson, J.H.; Ellingboe, J.; Mello, N.K. and Kuehnle, J.: Buprenorphine effects on luteinizing hormone and prolactin in male heroin addicts. Journal of Pharmacology and Experimental Therapeutics 220: 252–255 (1982).PubMedGoogle Scholar
  42. Miller, M.: Role of endogenous opioids in neurohypophysial function of man. Journal of Clinical Endocrinology and Metabolism 50: 1016–1020 (1980).PubMedCrossRefGoogle Scholar
  43. Misra, A.L.; Bloch, R.; Vardy, J.; Mulé, S.J. and Verebey, K.: Disposition of [15, 16-3H] naltrexone in the central nervous system of the rat. Drug Metabolism and Disposition 4: 276–280 (1976).PubMedGoogle Scholar
  44. Moore, R.A.; Smith, R.F.; McQuay, H.J. and Bullingham, R.E.S.: Sex and surgical stress. Anaesthesia 36: 263–267 (1981).PubMedCrossRefGoogle Scholar
  45. Nagashima, H.; Karamanian, A.; Malovany, R.; Radnay, P.; Ang, M.; Koerner, S. and Foldcs, F.F.: Respiratory and circulatory effects of intravenous butorphanol and morphine. Clinical Pharmacology and Therapeutics 19: 738–745 (1976).PubMedGoogle Scholar
  46. Neal, E.A.; Meffin, P.J.; Gregory, P.B. and Blaschke, T.F.: Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis. Gastroenterology 77: 96–102 (1979).PubMedGoogle Scholar
  47. Pfeffer, M.; Smyth, R.D.; Pittman, K.A. and Nardella, P.A.: Pharmacokinetics of subcutaneous and intramuscular butorphanol in dogs. Journal of Pharmaceutical Sciences 69: 801–803 (1980).PubMedCrossRefGoogle Scholar
  48. Pittman, K.A.; Smyth, R.D.; Losada, M.; Zighelboim, I.; Maduska, A.L. and Sunshine, A.: Human perinatal distribution of butorphanol. American Journal of Obstetrics and Gynecology 138: 797–800 (1980a).PubMedGoogle Scholar
  49. Pittman, K.A.; Smyth, R.D. and Mayol, R.F.: Serum levels of butorphanol by radioimmunoassay. Journal of Pharmaceutical Science 69: 160–163 (1980b).CrossRefGoogle Scholar
  50. Pond, S.M.; Tong, T.; Benowitz, N.L. and Jacob, P.: Enhanced bioavailability of pethidine and pentazocine in patients with cirrhosis of the liver. Australian and New Zealand Journal of Medicine 10: 515–519 (1980).PubMedCrossRefGoogle Scholar
  51. Romagnoli, A. and Keats, A.S.: Ceiling effect for respiratory depression by nalbuphine. Clinical Pharmacology and Therapeutics 27: 478–485 (1980).PubMedCrossRefGoogle Scholar
  52. Smyth, R.D.; Pittman, K.A. and Gaver, R.C.: Human pharmacokinetics and metabolism of butorphanol. Clinical Pharmacology and Therapeutics 25: 250 (1979).Google Scholar
  53. Tammisto, T. and Tigerstedt, I.: Comparison of analgesic effect of intravenous nalbuphine and pentazocine in patients with postoperative pain. Acta Anaesthesiologica Scandinavica 21: 390–394 (1977).PubMedCrossRefGoogle Scholar
  54. Verebey, K.; Volavka, J.; Mulé, S.J. and Resnick, R.B.: Naltrexone: Disposition, metabolism and effects after acute and chronic dosing. Clinical Pharmacology and Therapeutics 20: 315–328 (1976).PubMedGoogle Scholar
  55. Wall, M.E.; Brine, D.R. and Perez-Reyes, M.: Metabolism and disposition of naltrexone in man after oral and intravenous administration. Drug Metabolism and Disposition 9: 369–375 (1981).PubMedGoogle Scholar
  56. Wallenstein, S.L.; Kaiko, R.F.; Rogers, A.G. and Houde, R.W.: Clinical analgesic assays of buprenorphine and morphine (abstract). Clinical Pharmacology and Therapeutics 31: 278 (1982).Google Scholar
  57. Watson, P.J.Q.; McQuay, H.J.; Bullingham, R.E.S.; Allen, M.C. and Moore, R.A.: Single dose comparison of 0.3mg and 0.6mg of intravenous buprenorphine given postoperatively: Clinical effects and plasma concentrations. British Journal of Anaesthesia 54: 37–43 (1982).PubMedCrossRefGoogle Scholar
  58. Wilkinson, G.R. and Schenker, S.: Effects of liver diseases on drug disposition in man. Biochemical Pharmacology 25: 2675–2681 (1976).PubMedCrossRefGoogle Scholar
  59. Zierler, K.L.: Effect of circulating beds on tracer experiments or non-compartmental analysis. Annals of the New York Academy of Sciences 108: 106–116 (1963).PubMedCrossRefGoogle Scholar

Copyright information

© ADIS Press Australasia Pty Ltd. 1983

Authors and Affiliations

  • R. E. S. Bullingham
    • 1
  • H. J. McQuay
    • 1
  • R. A. Moore
    • 1
  1. 1.Pain Relief Research UnitAbingdon HospitalAbingdon, OxonEngland

Personalised recommendations